

Transgene files 2 patents for Liver & Breast Cancer Drugs

March 3, 2010

Transgene Biotek announced today that it has filed 2 patents for its cancer drug technologies based on its proprietary RNAi platform.

The first patent for a Liver Cancer drug was filed following excellent results demonstrated in the latest animal studies, and it covers a novel technology that employs an AAV vector system genetically modified by Transgene to efficiently express specific microRNA that silence a particular metastasis-promoting gene in liver cancer cells. Liver cancer is the fifth most common cancer in the world, and the third most common cause of cancer mortality.

The second patent, for a Breast Cancer drug, describes another novel technology developed by Transgene that employs an efficient system which expresses short interfering RNA cloned in a viral vector that silence a particular metastasis-promoting gene in breast cancer cells. This drug is specifically designed not only to treat primary Breast Cancer but also to fight against potential metastatic tumours. Worldwide, breast cancer is the most common cancer in women, representing 16% of all female cancers, and causes well over 500,000 deaths annually. This patent was also filed following exciting results in recent animal studies.

Both of these cancer drugs are built on Transgene's own novel RNAi platform, which has been validated by the results of the animal studies, and utilize a novel gene silencing technology to selectively knock-down specific cancer-producing gene targets. Transgene's ability to generate its own novel mutant vectors for highly efficient drug delivery, which is vital in the treatment of such cancers, also forms a part of both patents.

Transgene is expecting to file more patents on some of its other technologies shortly.